[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494725":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":38,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":7,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"GENETIC","whole genome sequencing","Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes",[14],{"name":15,"affiliation":5,"role":16},"Vania Broccoli, PhD","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+39 0226434616","broccoli.vania@hsr.it",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":26,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Milan","Italy","20132","IT",{"type":30,"coordinates":31},"Point",[32,33],12.59836,42.78235,{"lat":33,"lon":32},[36],{"name":15,"role":19,"phone":37,"phoneExt":7,"email":21},"0226434616",{"type":16,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Vania Broccoli","Head of CNR Unit","100494725","implementing-a-national-biobank-of-pd-with-wgs-and-functional-assessment-of-polygenic-inheritance-by-ipsc-technology-100494725",false,"NCT05721911","Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology","Implementing a National Biobank of Genetic, Sporadic and Prodromic Parkinson's Disease With Whole Genome Analysis and Functional Assessment of Polygenic Inheritance by iPSC Technology","Inclusion Criteria PD patients:\n\n* Presence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, onset asymmetric) one of which must be tremor or bradykinesia;\n* Absence of atypical symptoms such as: i) early postural instability, freezing phenomena, cognitive impairment, hallucinations, pathological involuntary movements, vertical gaze paralysis; ii) confirmed causes of secondary parkinsonism (focal lesions, drugs, substances toxic);\n* Documented response to L-dopa or dopamine agonist use (or lack of adequate therapeutic attempt with L-dopa or dopamine agonists).\n\nInclusion Criteria RBD patients:\n\n• Subjects affected by idiopathic RBD that will be selected according to the most recent criteria international classification of sleep disorders (ICSD-3).\n\nExclusion Criteria:\n\n* pre-existing psychiatric conditions;\n* Neurodegenerative neurological diseases such as multiple sclerosis, lateral sclerosis amyotrophic, Alzheimer's, neuromuscular pathologies, epilepsy;\n* diagnosis of dementia;\n* depression;\n* prolonged intake of anxiolytics, antidepressants, antipsychotics, hypnotic drugs, cognitive stimulants",true,"ALL","18 Years",{"count":52,"type":53},230,"ESTIMATED","OBSERVATIONAL","The genetic complexity and heterogeneity of the sporadic forms of Parkinson's disease (PD) are posing a formidable challenge to disentangle their direct molecular causes. To advance this research, we plan to coordinate our local biorepositories of PD biological specimens creating a standardized and integrated national resource. In this framework, we plan to collect more samples from additional sporadic PD cases and to extend the sampling to patients with REM sleep behavior disease. We plan a large campaign of whole genome sequencing including about 200 patients to identify rare genomic variants plausibly associated with these diseases. In addition, we will standardize the generation and quality control of iPSC lines to make available to the scientific community. Finally, we will combine iPSC technology and gene editing to functionally assess the relative impact of rare variants in coding regions inherited together as a polygenic trait previously identified in selected sporadic PD cases",[57,58],"Parkinson Disease","REM Sleep Behavior Disorder","2026-03-25",{"date":61,"type":62},"2026-03-30","ACTUAL",{"date":64,"type":62},"2023-10-30",{"date":66,"type":53},"2026-12",{"name":5,"class":6},1]